The effect of 5 α-reductase inhibitors on erectile function

Onder Canguven, Arthur Burnett

Research output: Contribution to journalArticle

Abstract

The 5 α-reductase inhibitors, which inhibit conversion of testosterone to dihydrotestosterone, are used for miscellaneous clinical applications, including the treatment of benign prostatic hyperplasia and male pattern hair loss, and for possible reduction of the risk of prostate cancer. Erectile dysfunction has been associated with 5 α-reductase inhibitors. Overall, reports in the literature suggest rates of erectile dysfunction to be between 0.8%-33% in men using these medications. However, randomized controlled studies report the rates of erectile dysfunction to be between 0.80%-15.8%. The possible risk association is that these medications impact androgen function, which is understood to contribute to normal erectile physiology. The 5α-reductase inhibitors result in a drop in median serum dihydrotestosterone levels by 60%-93% within 2 years, but there is no major change in testosterone levels. In this review, we surveyed studies on erectile dysfunction in patients treated with 5 α-reductase inhibitors and critically examined the evidence that associates 5 α-reductase inhibitors and erectile dysfunction. We conclude that 5 α-reductase inhibitors do not lead to erectile dysfunction to a significant degree, and we support the position that dihydrotestosterone is less relevant than testosterone in erectile function.

Original languageEnglish (US)
Pages (from-to)514-523
Number of pages10
JournalJournal of Andrology
Volume29
Issue number5
DOIs
StatePublished - Sep 2008

Fingerprint

Erectile Dysfunction
Oxidoreductases
Dihydrotestosterone
Testosterone
Alopecia
Prostatic Hyperplasia
Risk Reduction Behavior
Androgens
Prostatic Neoplasms
Serum

ASJC Scopus subject areas

  • Urology
  • Reproductive Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

The effect of 5 α-reductase inhibitors on erectile function. / Canguven, Onder; Burnett, Arthur.

In: Journal of Andrology, Vol. 29, No. 5, 09.2008, p. 514-523.

Research output: Contribution to journalArticle

@article{a9230b4defd04ccba6a6067545c0d2bc,
title = "The effect of 5 α-reductase inhibitors on erectile function",
abstract = "The 5 α-reductase inhibitors, which inhibit conversion of testosterone to dihydrotestosterone, are used for miscellaneous clinical applications, including the treatment of benign prostatic hyperplasia and male pattern hair loss, and for possible reduction of the risk of prostate cancer. Erectile dysfunction has been associated with 5 α-reductase inhibitors. Overall, reports in the literature suggest rates of erectile dysfunction to be between 0.8{\%}-33{\%} in men using these medications. However, randomized controlled studies report the rates of erectile dysfunction to be between 0.80{\%}-15.8{\%}. The possible risk association is that these medications impact androgen function, which is understood to contribute to normal erectile physiology. The 5α-reductase inhibitors result in a drop in median serum dihydrotestosterone levels by 60{\%}-93{\%} within 2 years, but there is no major change in testosterone levels. In this review, we surveyed studies on erectile dysfunction in patients treated with 5 α-reductase inhibitors and critically examined the evidence that associates 5 α-reductase inhibitors and erectile dysfunction. We conclude that 5 α-reductase inhibitors do not lead to erectile dysfunction to a significant degree, and we support the position that dihydrotestosterone is less relevant than testosterone in erectile function.",
author = "Onder Canguven and Arthur Burnett",
year = "2008",
month = "9",
doi = "10.2164/jandrol.108.005025",
language = "English (US)",
volume = "29",
pages = "514--523",
journal = "Journal of Andrology",
issn = "0196-3635",
publisher = "American Society of Andrology Inc.",
number = "5",

}

TY - JOUR

T1 - The effect of 5 α-reductase inhibitors on erectile function

AU - Canguven, Onder

AU - Burnett, Arthur

PY - 2008/9

Y1 - 2008/9

N2 - The 5 α-reductase inhibitors, which inhibit conversion of testosterone to dihydrotestosterone, are used for miscellaneous clinical applications, including the treatment of benign prostatic hyperplasia and male pattern hair loss, and for possible reduction of the risk of prostate cancer. Erectile dysfunction has been associated with 5 α-reductase inhibitors. Overall, reports in the literature suggest rates of erectile dysfunction to be between 0.8%-33% in men using these medications. However, randomized controlled studies report the rates of erectile dysfunction to be between 0.80%-15.8%. The possible risk association is that these medications impact androgen function, which is understood to contribute to normal erectile physiology. The 5α-reductase inhibitors result in a drop in median serum dihydrotestosterone levels by 60%-93% within 2 years, but there is no major change in testosterone levels. In this review, we surveyed studies on erectile dysfunction in patients treated with 5 α-reductase inhibitors and critically examined the evidence that associates 5 α-reductase inhibitors and erectile dysfunction. We conclude that 5 α-reductase inhibitors do not lead to erectile dysfunction to a significant degree, and we support the position that dihydrotestosterone is less relevant than testosterone in erectile function.

AB - The 5 α-reductase inhibitors, which inhibit conversion of testosterone to dihydrotestosterone, are used for miscellaneous clinical applications, including the treatment of benign prostatic hyperplasia and male pattern hair loss, and for possible reduction of the risk of prostate cancer. Erectile dysfunction has been associated with 5 α-reductase inhibitors. Overall, reports in the literature suggest rates of erectile dysfunction to be between 0.8%-33% in men using these medications. However, randomized controlled studies report the rates of erectile dysfunction to be between 0.80%-15.8%. The possible risk association is that these medications impact androgen function, which is understood to contribute to normal erectile physiology. The 5α-reductase inhibitors result in a drop in median serum dihydrotestosterone levels by 60%-93% within 2 years, but there is no major change in testosterone levels. In this review, we surveyed studies on erectile dysfunction in patients treated with 5 α-reductase inhibitors and critically examined the evidence that associates 5 α-reductase inhibitors and erectile dysfunction. We conclude that 5 α-reductase inhibitors do not lead to erectile dysfunction to a significant degree, and we support the position that dihydrotestosterone is less relevant than testosterone in erectile function.

UR - http://www.scopus.com/inward/record.url?scp=52949152825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949152825&partnerID=8YFLogxK

U2 - 10.2164/jandrol.108.005025

DO - 10.2164/jandrol.108.005025

M3 - Article

C2 - 18421068

AN - SCOPUS:52949152825

VL - 29

SP - 514

EP - 523

JO - Journal of Andrology

JF - Journal of Andrology

SN - 0196-3635

IS - 5

ER -